Engineering armored CAR‑T cells to overcome the solid tumor microenvironment

CAR‑T cell therapies have achieved remarkable outcomes in hematologic malignancies, yet solid tumors remain a formidable challenge due to target antigen heterogeneity, poor T cell infiltration, and an immunosuppressive tumor microenvironment. This article explores next‑generation armored CAR‑T cell strategies developed in the Priceman laboratory, including the use of membrane‑tethered and fusion‑format IL‑12 to overcome macrophage‑mediated suppression via a programmed death‑ligand 1 (PD‑L1)–IL‑12 fusion protein, approaches to address antigen escape in tumor‑associated glycoprotein‑72 (TAG72)-targeted ovarian cancer therapy, and the application of oncolytic viruses as a universal antigen delivery platform for combinatorial solid tumor targeting.

Next-generation armored CAR-T cells — engineered with IL-12, PD-L1 blockade, and oncolytic virus antigen delivery — offer new strategies to overcome the immunosuppressive solid tumor microenvironment.

What you will learn

01

Phase 1 PSCA CAR-T outcomes in metastatic prostate cancer

02

IL-12 and PD-L1–IL-12 fusion strategies to reprogram the TME

03

Oncolytic virus delivery as a universal CAR-T targeting platform

Engineering strategies

1

PSCA/TAG72 CAR-T design

2

Armoring with mbIL-12 or PD-L1–IL-12

3

TME remodeling

4

OV combinatorial targeting

Key findings

PSA reductions in 50% of patients in Phase 1; one patient showed bone metastasis reduction and increased T cell infiltration

PD-L1–IL-12 fusion CAR-T cells produced curative responses in all treated animals vs modest activity with PSCA CAR-T alone

Optimized TAG72 CAR-T achieved curative responses after a single infusion in ovarian cancer; now in NIH-funded Phase 1

Key interests

CAR-T cells Solid tumors TME IL-12 PD-L1 Antigen escape Oncolytic virus Ovarian cancer